Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.78 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1726021 | 0.82 | L3MBTL1 (0.68) | L3MBTL1FKBP1ATSHRPOLBLMNA | |
| SCHEMBL3710498 | 0.82 | ALDH1A1 (0.57) | L3MBTL1TSHRALDH1A1RAB9AHTT | |
| SCHEMBL48570 | 0.82 | ALDH1A1 (0.57) | L3MBTL1POLBALDH1A1RAB9AHTT | |
| SCHEMBL24313327 | 0.81 | L3MBTL1 (0.78) | L3MBTL1FKBP1ATSHRPOLBLMNA | |
| SCHEMBL428816 | 0.81 | L3MBTL1 (0.78) | L3MBTL1FKBP1ATSHRPOLBLMNA | |
| SCHEMBL14654219 | 0.80 | L3MBTL1 (0.70) | L3MBTL1FKBP1ATSHRPOLBLMNA | |
| SCHEMBL18026620 | 0.80 | L3MBTL1 (0.70) | L3MBTL1FKBP1ATSHRPOLBLMNA | |
| SCHEMBL5986412 | 0.80 | L3MBTL1 (0.70) | L3MBTL1FKBP1ATSHRPOLBLMNA | |
| SCHEMBL31007038 | 0.80 | ALDH1A1 (0.59) | L3MBTL1POLBALDH1A1RAB9AHTT | |
| SCHEMBL19818799 | 0.80 | L3MBTL1 (0.64) | L3MBTL1FKBP1ATSHRPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-18 | — | — | US | disclosed |
| EP-4043460-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | Merck Patent GmbH (DE) | 2022-08-17 | — | — | EP | disclosed |
| EP-3784666-B1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-03-16 | — | — | EP | disclosed |
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-27 | — | — | US | disclosed |
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| EP-2858991-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9981959-B2 | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2564857-B1 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
| US-20110190271-A1 | 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7884111-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100210635-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | L3MBTL1 2445/4885FKBP1A 2706/4885TSHR 4297/4885 |
| US-20100210635-A1 | RENIN INHIBITORS | REN, ACE, AGT | L3MBTL1 4882/4885FKBP1A 2878/4885TSHR 2947/4885 |
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | L3MBTL1 3170/4885FKBP1A 177/4885TSHR 3810/4885 |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | NQO1, TXN2, MPO | L3MBTL1 3421/4885FKBP1A 2679/4885TSHR 3136/4885 |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | L3MBTL1 2445/4885FKBP1A 2706/4885TSHR 4297/4885 |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | L3MBTL1 2445/4885FKBP1A 2706/4885TSHR 4297/4885 |
| US-20110190271-A1 | 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents | MKI67, TYMP, PCNA | L3MBTL1 2445/4885FKBP1A 2706/4885TSHR 4297/4885 |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | L3MBTL1 3170/4885FKBP1A 177/4885TSHR 3810/4885 |
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | L3MBTL1 3170/4885FKBP1A 177/4885TSHR 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.